IFPMA Announces Lundbeck and Innovative Pharma as New Members

Geneva, 23 June 2011 – The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Lundbeck and Innovative Pharma have joined the Federation, thus bringing its membership up to 28 leading international companies and 45 national and regional industry associations.

Lundbeck is a global pharmaceutical company conducting research for the treatment of disorders in the central nervous system (CNS), including depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, epilepsy and insomnia.

According to the World Health Organization, WHO, more than 700 million cases of brain disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. IFPMA Director General Eduardo Pisani said: “With one in three people suffering from mental disorders at some point during their life, diagnoses and discrimination of mental illness puts a major strain on societies and economies as poor mental health has a direct impact on people’s ability to work. In addition, there is increasing evidence for links between diseases such as diabetes and mental health. This underlines the need for joined up thinking when trying to tackle these issues at a policy level.”

The Association “Innovative PHARMA” (InPharma) is a non-profit organization of global research-based pharmaceutical companies operating in Russia. Its members are Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Merck Sharp&Dohme, Novartis Pharma, Novo Nordisk and Pfizer. InPharma has a keen interest to provide the perspective of its members operating in Russia on global policy issues that foster biopharmaceutical innovation, and that address quality standards of medicines as well as ethical business practices.
About the IFPMA:
The International Federation of Pharmaceutical Manufacturers & Associations is the global non-profit NGO representing the research-based pharmaceutical industry, including the biotech and vaccine sectors. Its members comprise 28 leading international companies and 45 national and regional industry associations covering low, middle and high income countries. The industry’s R&D pipeline contains hundreds of new medicines and vaccines being developed to address global disease threats, including cancer, heart disease, HIV/AIDS and malaria. The IFPMA Clinical Trials Portal (www.ifpma.org/ClinicalTrials), the IFPMA’s Ethical Promotion online resource (www.ifpma.org/EthicalPromotion/) and its Developing World Health Partnerships Directory (www.ifpma.org/HealthPartnerships) help make the industry’s activities more transparent. The IFPMA supports a wide range of WHO technical activities, notably those relating to medicine efficacy, quality and safety. It also provides the secretariat for the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

For further information, please contact:
Abigail Jones
E-mail: Abigail@acumen-publicaffairs.com
Tel: +32 475 41 09 76

Web: www.ifpma.org